SCM
KIN

Segantii Capital Management’s Kindred Biosciences, Inc. KIN Stock Holding History

Segantii Capital Management’s Portfolio KIN Stock Details KIN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-11,140
Closed -$79K – 321
2017
Q1 		$79K Buy
+11,140
New +$69.8K 0.01% 225

Other funds holding KIN

PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
CC
Cannell Capital Alta, Wyoming $163M AUM 40.62% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Segantii Capital Management's KIN Position: Q2 2017 in Review

Segantii Capital Management sold out of Kindred Biosciences, Inc. (KIN) in Q2 2017, closing a stake of 11,140 shares — an estimated $79K sold.

Segantii Capital Management first reported a position in KIN in Q1 2017 and held it in 1 quarter. The position peaked at $79K in Q1 2017. 66 funds tracked by Wall St. Rank hold KIN as of Q2 2017.

  • Segantii Capital Management reported no remaining Kindred Biosciences, Inc. position as of Q2 2017 after selling out during the quarter.
  • Segantii Capital Management sold 11,140 Kindred Biosciences, Inc. shares in Q2 2017, an estimated $79K.
  • Segantii Capital Management first reported a position in Kindred Biosciences, Inc. in Q1 2017 and held it in 1 quarter.
  • Segantii Capital Management's Kindred Biosciences, Inc. position peaked at $79K in Q1 2017.
  • 66 funds tracked by Wall St. Rank held Kindred Biosciences, Inc. as of Q2 2017.

Based on Segantii Capital Management's 13F filing for Q2 2017, filed 2 Aug 2017.